Other Clinical Trial - Patient-reported Outcomes in Vericiguat-treated

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF — VITALITY-HFpEF

Chronic Heart Failure With Preserved Ejection Fraction Clinical Trial

Official title:
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Trial to Evaluate the Efficacy and Safety of the Oral sGC stImulator Vericiguat to Improve Physical Functioning in Activities of Daily Living in Patients With Heart Failure and Preserved Ejection Fraction (VITALITY-HFpEF)

NCT number	NCT03547583
Study type	Interventional
Source	Bayer
Contact
Status	Completed
Phase	Phase 2
Start date	June 15, 2018
Completion date	November 4, 2019

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF — VITALITY-HFpEF

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms